Literature DB >> 19724769

Persistent Psychosis and Medical Complications After a Single Ingestion of MDMA "Ecstasy": A Case Report and Review of the Literature.

Mordecai N Potash1, Kimberly A Gordon, Kristy L Conrad.   

Abstract

We describe a case report of persistent psychosis and severe medical complications in a previously healthy, 19-year-old African-American man after a single ingestion of what was purported to be "Ecstasy." We detail the psychiatric symptoms and medical complications that resulted in several weeks of hospitalization in both medical intensive care and psychiatric units. Furthermore, we describe changes in the demographics of the use of Ecstasy and present the current understanding of the cause of neurotoxicity after Ecstasy use when it occurs. We conclude by suggesting actions clinicians can take to ameliorate the negative consequences of Ecstasy use.

Entities:  

Keywords:  Ecstacy; MDMA; cardiomyopathy; seizure disorder; substance abuse

Year:  2009        PMID: 19724769      PMCID: PMC2728937     

Source DB:  PubMed          Journal:  Psychiatry (Edgmont)        ISSN: 1550-5952


  10 in total

1.  Persistent psychosis after a single ingestion of 'ecstasy'.

Authors:  J Van Kampen; M Katz
Journal:  Psychosomatics       Date:  2001 Nov-Dec       Impact factor: 2.386

2.  Ecstasy in the brain: a model for neuroimaging.

Authors:  Robin A Hurley; Liesbeth Reneman; Katherine H Taber
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2002       Impact factor: 2.198

3.  Neuropsychiatric consequences (atypical psychosis and complex-partial seizures) of ecstasy use: possible evidence for toxicity-vulnerability predictors and implications for preventative and clinical care.

Authors:  Marco Vecellio; Christian Schopper; Jiri Modestin
Journal:  J Psychopharmacol       Date:  2003-09       Impact factor: 4.153

4.  Chronic paranoid psychosis after misuse of MDMA ("ecstasy")

Authors:  P McGuire; T Fahy
Journal:  BMJ       Date:  1991-03-23

5.  The struggle for mental healthcare in new orleans-one case at a time.

Authors:  Mordecai N Potash
Journal:  Psychiatry (Edgmont)       Date:  2008-07

6.  The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents.

Authors:  Roland W Freudenmann; Florian Oxler; Sabine Bernschneider-Reif
Journal:  Addiction       Date:  2006-09       Impact factor: 6.526

7.  Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy")

Authors:  J A Henry; K J Jeffreys; S Dawling
Journal:  Lancet       Date:  1992-08-15       Impact factor: 79.321

Review 8.  Neurotoxicity of methylenedioxyamphetamines (MDMA; ecstasy) in humans: how strong is the evidence for persistent brain damage?

Authors:  E Gouzoulis-Mayfrank; J Daumann
Journal:  Addiction       Date:  2006-03       Impact factor: 6.526

Review 9.  Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective.

Authors:  R Thomasius; P Zapletalova; K Petersen; R Buchert; B Andresen; L Wartberg; B Nebeling; A Schmoldt
Journal:  J Psychopharmacol       Date:  2006-03       Impact factor: 4.153

Review 10.  Club drugs: methylenedioxymethamphetamine, flunitrazepam, ketamine hydrochloride, and gamma-hydroxybutyrate.

Authors:  Kelly M Smith; Lisa L Larive; Frank Romanelli
Journal:  Am J Health Syst Pharm       Date:  2002-06-01       Impact factor: 2.637

  10 in total
  8 in total

1.  Persistent Psychosis After a Single Ingestion of "Ecstasy" (MDMA).

Authors:  Ankit Patel; Toby Moreland; Fasiha Haq; Fatima Siddiqui; Melissa Mikul; Huma Qadir; Shakeel Raza
Journal:  Prim Care Companion CNS Disord       Date:  2011

2.  Preliminary analysis of positive and negative syndrome scale in ketamine-associated psychosis in comparison with schizophrenia.

Authors:  Ke Xu; John H Krystal; Yuping Ning; Da Chun Chen; Hongbo He; Daping Wang; Xiaoyin Ke; Xifan Zhang; Yi Ding; Yuping Liu; Ralitza Gueorguieva; Zuoheng Wang; Diana Limoncelli; Robert H Pietrzak; Ismene L Petrakis; Xiangyang Zhang; Ni Fan
Journal:  J Psychiatr Res       Date:  2014-12-24       Impact factor: 4.791

3.  Additive Effects of Former Methylenedioxymethamphetamine and Cannabis Use on Subclinical Psychotic Symptoms.

Authors:  Berker Duman; Nilay Sedes; Bora Baskak
Journal:  Noro Psikiyatr Ars       Date:  2017-03-01       Impact factor: 1.339

Review 4.  Neurotoxicity of methamphetamine and 3,4-methylenedioxymethamphetamine.

Authors:  Laura E Halpin; Stuart A Collins; Bryan K Yamamoto
Journal:  Life Sci       Date:  2013-07-24       Impact factor: 5.037

Review 5.  Substance-Induced Psychoses: An Updated Literature Review.

Authors:  Alessio Fiorentini; Filippo Cantù; Camilla Crisanti; Guido Cereda; Lucio Oldani; Paolo Brambilla
Journal:  Front Psychiatry       Date:  2021-12-23       Impact factor: 4.157

6.  COMTVal158Met polymorphism is associated with ecstasy (MDMA)-induced psychotic symptoms in the Turkish population.

Authors:  Hasan Mervan Aytac; Yasemin Oyaci; Pinar Cetinay Aydin; Mustafa Pehlivan; Sacide Pehlivan
Journal:  Neurosciences (Riyadh)       Date:  2022-01       Impact factor: 0.735

7.  Symptomatological features of patients with and without Ecstasy use during their first psychotic episode.

Authors:  Fabio Rugani; Silvia Bacciardi; Luca Rovai; Matteo Pacini; Angelo Giovanni Icro Maremmani; Joseph Deltito; Liliana Dell'osso; Icro Maremmani
Journal:  Int J Environ Res Public Health       Date:  2012-06-27       Impact factor: 3.390

8.  Impact of Pharmaceutical Impurities in Ecstasy Tablets: Gas Chromatography-Mass Spectrometry Study.

Authors:  Amir Jalali; Amir Hatamie; Tahere Saferpour; Alireza Khajeamiri; Tahere Safa; Foad Buazar
Journal:  Iran J Pharm Res       Date:  2016       Impact factor: 1.696

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.